What is NEXGEL?
NEXGEL operates at the intersection of healthcare and materials science, specializing in the development and manufacturing of advanced hydrogel-based patches. By leveraging electron-beam cross-linking, the company eliminates the need for harsh chemical adhesives, providing a superior delivery mechanism for active ingredients in wound care, cosmetics, and over-the-counter medical applications. Its market position is defined by a commitment to biocompatibility and therapeutic efficacy, catering to a growing demand for non-irritating, high-performance transdermal solutions. The company's ability to scale these specialized materials into commercial-grade products positions it as a critical player in the evolving landscape of medical device innovation.
How much funding has NEXGEL raised?
NEXGEL has raised a total of $15.5M across 3 funding rounds:
Debt
$127K
Stock Offering
$14.2M
Stock/Share Issuance
$1.2M
Debt (2021): $127K with participation from PPP
Stock Issuance/Offering (2022): $14.2M, investors not publicly disclosed
Stock/Share Issuance (2026): $1.2M, investors not publicly disclosed
Key Investors in NEXGEL
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for NEXGEL?
With the recent capital injection, NEXGEL is poised to transition into a phase of aggressive operational scaling and market penetration. The strategic roadmap likely involves increasing production capacity to meet the rising demand for its proprietary hydrogel patches while simultaneously investing in R&D to broaden its transdermal delivery portfolio. As the company matures, the focus will shift toward securing deeper partnerships within the pharmaceutical and cosmetic sectors, leveraging its unique material science advantage to capture market share from legacy adhesive manufacturers. This growth trajectory suggests a long-term commitment to establishing NEXGEL as the industry standard for gentle, effective, and high-water-content therapeutic delivery systems.
See full NEXGEL company page
